jilibet 004 com
CLEMSON 75, PENN STATE 67
Barry Odom begins Purdue career with larger NIL budget and questions about payment dispute at UNLV
By MICHELLE L. PRICE WEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump’s supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump’s movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump’s Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer , a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer’s comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks , whom Trump has tapped to be the “White House A.I. & Crypto Czar.” Musk and Ramaswamy, whom Trump has tasked with finding ways to cut the federal government , weighed in, defending the tech industry’s need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump’s world and what his political movement stands for. Trump has not yet weighed in on the rift, and his presidential transition team did not respond to a message seeking comment. Musk, the world’s richest man who has grown remarkably close to the president-elect , was a central figure in the debate, not only for his stature in Trump’s movement but his stance on the tech industry’s hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. But critics have said they undercut U.S. citizens who could take those jobs. Some on the right have called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry’s need to bring in foreign workers. “There is a permanent shortage of excellent engineering talent,” he said in a post. “It is the fundamental limiting factor in Silicon Valley.” Related Articles National Politics | Should the U.S. increase immigration levels for highly skilled workers? National Politics | Trump threat to immigrant health care tempered by economic hopes National Politics | In states that ban abortion, social safety net programs often fail families National Politics | Court rules Georgia lawmakers can subpoena Fani Willis for information related to her Trump case National Politics | New 2025 laws hit hot topics from AI in movies to rapid-fire guns Trump’s own positions over the years have reflected the divide in his movement. His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He has focused on immigrants who come into the U.S. illegally but he has also sought curbs on legal immigration , including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program “very bad” and “unfair” for U.S. workers. After he became president, Trump in 2017 issued a “Buy American and Hire American” executive order , which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump’s businesses, however, have hired foreign workers, including waiters and cooks at his Mar-a-Lago club , and his social media company behind his Truth Social app has used the the H-1B program for highly skilled workers. During his 2024 campaign for president, as he made immigration his signature issue, Trump said immigrants in the country illegally are “poisoning the blood of our country” and promised to carry out the largest deportation operation in U.S. history. But in a sharp departure from his usual alarmist message around immigration generally, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. “I think you should get automatically, as part of your diploma, a green card to be able to stay in this country,” he told the “All-In” podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump’s budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes.US needs to do more make cyber attackers pay, Trump adviser says
A UK ticket-holder has won £177 million in Tuesday’s EuroMillions draw. But it is not the largest prize a person has won in this country. Here are the 10 biggest UK lottery winners – all from EuroMillions draws – and what some of them did with their fortunes. – Anonymous, £195,707,000 A UK ticket-holder scooped the record EuroMillions jackpot of £195 million on July 19 2022 – the biggest National Lottery win of all time. – Joe and Jess Thwaite, £184,262,899.10 Joe and Jess Thwaite, from Gloucester, scooped a then record-breaking £184,262,899 with a Lucky Dip ticket for the draw on May 10 2022. At the time, Joe was a communications sales engineer, and Jess ran a hairdressing salon with her sister. – Unclaimed ticket holder, £177 million Tuesday’s winner is wealthier than former One Direction member Harry Styles and heavyweight boxer Anthony Joshua, who are both worth £175 million, according to the latest Sunday Times Rich List. Players have been urged to check their tickets to see if they can claim the prize. – Anonymous, £170,221,000 The fourth biggest winner of the National Lottery to date scooped £170 million in October 2019, after matching all the numbers in a Must Be Won draw. – Colin and Chris Weir, £161,653,000 Colin and Chris Weir, from Largs, North Ayrshire, bagged their historic winnings in July 2011, making them the biggest UK winners at the time. Colin used £2.5 million of his fortune to invest in his beloved Partick Thistle Football Club, which led to one of the stands at the stadium being named after him. He later acquired a 55% shareholding in the club, which was to be passed into the hands of the local community upon his death. He died in December 2019, aged 71. The couple also set up the Weir Charitable Trust in 2013 and donated £1 million to the Scottish independence referendum in 2014. They divorced in the same year as Colin’s death. – Adrian and Gillian Bayford, £148,656,000 Adrian and Gillian won 190 million euros in a EuroMillions draw in August 2012, which came to just over £148 million. The couple bought a Grade II listed estate in Cambridgeshire, complete with cinema and billiards room, but it was sold in 2021, some years after the pair divorced, as reported by The Mirror. – Anonymous, £123,458,008 The seventh biggest National Lottery winner won a Superdraw rollover jackpot in June 2019, and decided not to go public with their success. – Anonymous, £122,550,350 After nine rollovers, one lucky anonymous ticket-holder bagged more than £122 million in April 2021. – Anonymous, £121,328,187 Another of the UK’s top 10 lottery winners found their fortune through a Superdraw jackpot rollover, this time in April 2018. – Frances and Patrick Connolly, £114,969,775 Former social worker and teacher Frances set up two charitable foundations after she and her husband won almost £115 million on New Year’s Day 2019. She estimates that she has already given away £60 million to charitable causes, as well as friends and family. She considers helping others to be an addiction, saying: “It gives you a buzz and it’s addictive. I’m addicted to it now.”
The Minister of Aviation and Aerospace Development, Festus Keyamo, has defended his decision to approve a private airstrip amid rising concerns and allegations of preferential treatment. Keyamo said this on the ‘This Morning’ programme on Arise News on Sunday. Where he stressed the importance of fairness and adherence to legal processes in granting approvals for private airstrips across Nigeria. “You can’t single out an individual in a country like this when you have given the same right to so many people and say withdraw that particular one. On what basis?” Keyamo asked. “The people have not breached any terms upon which we gave them the license. If you single them out, the constitution says you should not discriminate against any Nigerian. They are following the rules.” Keyamo explained that the approval process for the airstrip was rigorous and took over a year to complete. “It took me one year to approve that airstrip because we went through so many processes. By law, I said the minister would approve. That is what the law says. And it came to me. I looked at all the processes. I approved,” he said. Related News Tinubu arrives Immigration HQ to unveil technology complex Keyamo, FCCPC differ on Air Peace probe Keyamo to inaugurate Abia airport project next week The minister rejected accusations that the approval could be interpreted as favouritism, emphasising that similar permissions have been granted across the country. “Why should I not approve when others have been approved across the country? That is why we must be careful not to see this as an attack on the church. Once they have fulfilled the obligations, why not?” he questioned. Keyamo also addressed security concerns, assuring Nigerians that stringent measures are in place for private airstrips. He noted that no private aircraft can depart directly from an airstrip to an international destination without undergoing thorough checks at a designated airport. “You cannot take off from any private airstrip in Nigeria and fly outside the country. This is not possible. You must first land at an international airport. You will be well-processed and checked before you fly out. If you are flying in, you must first land at an international airport. You will be processed before you fly to your private airstrip,” he explained. Recall that this is following the House of Rep’s instruction to the Ministry of Aviation and Aerospace to stop the issuance of airstrip licenses to private individuals and organisations. They also called for the withdrawal of licenses already granted to Living Faith Church, as well as to other private individuals and organisations, to safeguard national security.Brazil’s federal police last Thursday formally accused Mr Bolsonaro and 36 other people of attempting a coup. They sent their 884-page report to the Supreme Court, which lifted the seal. “The evidence collected throughout the investigation shows unequivocally that then-president Jair Messias Bolsonaro planned, acted and was directly and effectively aware of the actions of the criminal organisation aiming to launch a coup d’etat and eliminate the democratic rule of law, which did not take place due to reasons unrelated to his desire,” the document said. At another point, it says: “Bolsonaro had full awareness and active participation.” Mr Bolsonaro, who had repeatedly alleged without evidence that the country’s electronic voting system was prone to fraud, called a meeting in December 2022, during which he presented a draft decree to the commanders of the three divisions of the armed forces, according to the police report, signed by four investigators. The decree would have launched an investigation into suspicions of fraud and crimes related to the October 2022 vote, and suspended the powers of the nation’s electoral court. The navy’s commander stood ready to comply, but those from the army and air force objected to any plan that prevented Luiz Inacio Lula da Silva’s inauguration, the report said. Those refusals are why the plan did not go ahead, according to witnesses who spoke to investigators. Mr Bolsonaro never signed the decree to set the final stage of the alleged plan into action. Mr Bolsonaro has repeatedly denied any wrongdoing or awareness of any plot to keep him in power or oust his leftist rival and successor. “No one is going to do a coup with a reserve general and half a dozen other officers. What is being said is absurd. For my part, there has never been any discussion of a coup,” Mr Bolsonaro told journalists in the capital Brasilia on Monday. “If someone came to discuss a coup with me, I’d say, that’s fine, but the day after, how does the world view us?” he added. “The word ‘coup’ has never been in my dictionary.” The top court has passed the report on to prosecutor-general Paulo Gonet. He will decide whether to formally charge Mr Bolsonaro. Rodrigo Rios, a law professor at the PUC university in the city of Curitiba, said Mr Bolsonaro could face up to a minimum of 11 years in prison if convicted on all charges. “A woman involved in the January 8 attack on the Supreme Court received a 17-year prison sentence,” Mr Rios told the Associated Press, noting that the former president is more likely to receive 15 years or more if convicted. “Bolsonaro’s future looks dark.” Ahead of the 2022 election, Mr Bolsonaro repeatedly alleged that the election system, which does not use paper ballots, could be tampered with. The top electoral court later ruled that he had abused his power to cast unfounded doubt on the voting system, and ruled him ineligible for office until 2030. Still, he has maintained that he will stand as a candidate in the 2026 race. Since Mr Bolsonaro left office, he has been targeted by several investigations, all of which he has chalked up to political persecution. Federal police have accused him of smuggling diamond jewellery into Brazil without properly declaring them and directing a subordinate to falsify his and others’ Covid-19 vaccination statuses. Authorities are also investigating whether he incited the riot on January 8 2022 in which his followers ransacked the Supreme Court and presidential palace in Brasilia, seeking to prompt intervention by the army that would oust Mr Lula from power. Mr Bolsonaro had left for the United States days before Mr Lula’s inauguration on January 1 2023 and stayed there for three months, keeping a low profile. The police report unsealed on Tuesday alleges he was seeking to avoid possible imprisonment related to the coup plot, and also await the uprising that took place a week later.
'A Pearl Harbor moment': Fox News host amps up hysteria over drone sightingsUS agencies should use advanced technology to identify mysterious drones, Schumer saysWYLIE, Texas and LEXINGTON, Ky., Nov. 22, 2024 (GLOBE NEWSWIRE) — LearnEV+ and CarTechIQ have joined forces to launch GlobalTechIQ, Inc., a joint venture delivering groundbreaking AI diagnostic technology for heavy-duty and off-highway vehicle repairs. This collaboration, operating under the name HeavyDutyIQ, leverages live, context-based AI solutions to transform repair processes and empower technicians with real-time, accurate recommendations. GlobalTechIQ’s AI assistant processes data from a broad array of sources, including heavy-duty OEMs, tier 1 suppliers, and industry veterans. By analyzing these inputs in real-time, the system provides context-aware, live recommendations tailored to specific symptoms and diagnostic trouble codes. This ensures technicians receive the most relevant and actionable solutions instantly. “Repair shops face increasing complexity in diagnostics, electrical system repairs, and efficient troubleshooting are some of the key challenges faced by HD technicians and repair facilities today. Adding focused AI repair assistance technology to the diagnosis and repair process will drastically reduce diagnostic time and non-productive bay time by having AI-driven probable repair solutions available for the technician,” said John J. Stoeckinger, CEO of LearnEV+. “Keeping up with ever-changing systems technology on today’s vehicles is a challenge for all repair shops. In the passenger car and light duty market, our AI assistance technology provides probability-ranked repair recommendations with fast cycle times. We expect to offer similar results in the heavy-duty and off-road markets,” said Dean Ricciardulli, CEO of CarTechIQ Inc. Learn EV, Inc. is an E-commerce training platform that educates technicians in the electric vehicles space. Using virtual and augmented reality headsets to support the platform. Learn EV, Inc. leverages the assets and industry expertise of “Independent Truck Repair Group” (iTRG) to accelerate the Platform. CarTechIQ, Inc. is a leading innovator in AI-powered automotive service and support. By using specialized AI and open large language models, CarTechIQ, Inc. equips technicians and software providers with advanced tools for efficient, informed decision-making. The company’s mission is to transform the transportation industry by providing unparalleled guidance and cutting-edge technology. For more information contact or . John J. Stoeckinger Chief Executive Officer of LearnEV+
-- SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response -- -- SIGNAL-AD Phase 2a clinical trial in atopic dermatitis demonstrated promising findings in Part A but did not meet primary endpoint in Part B -- -- Across both trials, bempikibart was observed to be safe and well tolerated; demonstrated potent IL-7 and TSLP inhibition via changes in both Th2 biomarkers and T-cells, and desired target engagement -- -- Based on these results, Company plans to advance bempikibart in patients with AA -- WALTHAM, Mass. , Dec. 10, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914), which identified encouraging clinical activity in patients with alopecia areata (AA). The Company plans to expand the SIGNAL-AA Phase 2a clinical trial and enroll additional patients evaluating bempikibart in AA. "We are pleased with the emerging signals observed in the SIGNAL-AA Phase 2a clinical trial and based upon these, the positive biomarker data and well tolerated safety profile observed across both trials, we plan to enroll additional patients into the SIGNAL-AA clinical trial to further explore the clinical effects of bempikibart in this patient population. We believe bempikibart has the potential to be an important new treatment option in a disease needing new and safer alternatives to currently approved agents," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "We are disappointed that the SIGNAL-AD trial did not achieve its primary endpoint. Based upon the findings, including the high placebo rate, we plan to conduct a review to better understand the results." "Results from our analysis of SIGNAL-AA showed clinically meaningful activity and a safety profile that we believe is differentiated from the currently approved therapies for AA. We are encouraged by our findings from this clinical trial, and we look forward to advancing bempikibart as a potential treatment for AA," said Jason Campagna , M.D., Ph.D., Chief Medical Officer of Q32 Bio. "On behalf of Q32 Bio, I want to express my gratitude to the patients, their caregivers, and clinical trial sites that participated across both our bempikibart Phase 2a trials." The Company is also providing an update on the SIGNAL-AD clinical trial in patients with atopic dermatitis (AD). Although the Company is reporting promising findings in Part A, the trial did not meet its primary endpoint in Part B. Q32 Bio plans to conduct a review of the results. Topline Results from SIGNAL-AA Phase 2a Clinical Trial: SIGNAL-AA is a Phase 2a, randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating bempikibart in adult patients with severe and very severe AA (baseline Severity of Alopecia Tool (SALT) scores of 50-100) treated over 24 weeks, with follow-up through 36 weeks. The study is being conducted to evaluate the efficacy and safety of bempikibart 200 mg administered subcutaneously (SC), every-other-week (Q2W) compared to placebo. A total of 44 patients were enrolled in the trial with a primary endpoint of the mean relative percent change in SALT score at 24 weeks compared with baseline. Following database lock, one site was excluded from the efficacy analysis based on marked protocol violations of entry criteria. This resulted in the removal of three placebo patients, rendering the planned statistical analyses for the primary endpoint inappropriate due to the reduced sample size. On a post-hoc analysis of the remaining per-protocol population of patients with AA (n=27), bempikibart demonstrated an improvement in hair re-growth compared to placebo: Bempikibart was observed to be safe and well tolerated in the SIGNAL-AA trial. There were no serious adverse events (SAE) or Grade 3 or higher adverse events related to treatment. "Advancing bempikibart in AA is supported by preclinical data demonstrating the potential of IL-7Rα inhibition in this disease, and now the resulting data from SIGNAL-AA demonstrated the clinical potential of an IL-7Rα inhibitor in AA. I am encouraged by the biomarker data that provide evidence of biological activity, the safety profile of bempikibart, and the clinical signal of hair regrowth in patients," said Brett King , M.D., Ph.D., of Dermatology Physicians of Connecticut , and former Associate Professor of Dermatology, Yale University School of Medicine . "I believe these clinical results are promising and warrant further advancement to expand upon these findings." Q32 Bio plans to enroll approximately 20 additional patients in a Part B expansion of the SIGNAL-AA Phase 2a clinical trial to further evaluate bempikibart in AA, including a loading regimen. The Company will defer enrollment into the planned Phase 2 clinical trial of ADX-097 in ANCA-Associated Vasculitis (AAV), previously expected to begin in 2025, to focus efforts on continued enrollment in the ongoing bempikibart AA and ADX-097 renal basket Phase 2 clinical trials. Topline Results from SIGNAL-AD Phase 2a Clinical Trial: SIGNAL-AD is a two-part Phase 2a, randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating bempikibart in adult patients with persistent, moderate-to-severe AD. Part A (n=15) was conducted to evaluate safety, pharmacokinetics (PK), and to enable dose selection for Part B of the clinical trial. Part A was randomized 2:1 between bempikibart and placebo in each of two dose cohorts of 2mg/kg or 3mg/kg Q2W SC for 12 weeks. In Part A, at week 14, improvement in average EASI score from baseline was 58% in patients treated with 2mg/kg Q2W SC and 84% in patients treated at 3mg/kg Q2W SC, and 72% on a pooled basis, compared to 38% in patients treated with placebo. In Part B, which evaluated both efficacy and safety of bempikibart compared to placebo, patients were enrolled 1:1 in the bempikibart 200 mg Q2W SC (n=52) and placebo (n=54) arms for 12 weeks of treatment. The primary endpoint is the mean percent change from baseline to week 14 in the Eczema Area and Severity Index (EASI) score. At week 14, data from Part B demonstrated that patients treated with bempikibart showed a 74% improvement in average EASI from baseline, compared to 76% for the placebo group (p= not statistically significant). Results of the primary endpoint were generally consistent when stratified for pre-specified baseline entry criteria. Bempikibart was observed to be safe and well tolerated in the SIGNAL-AD trial. There were no serious adverse events (SAE) or Grade 3 or higher adverse events related to treatment. Q32 Bio plans to conduct a review of the SIGNAL-AD results. Biomarker Results in SIGNAL-AD and SIGNAL-AA: Across SIGNAL-AD and SIGNAL-AA, bempikibart at 200mg Q2W SC demonstrated favorable PK and target engagement as demonstrated by substantial reductions in biomarkers of Th2 and Th1. These results include: Q32 Bio believes these results demonstrate that bempikibart is a potent inhibitor of both TSLP and IL-7 signaling as evidenced by robust changes in both Th2 biomarkers and T-cells. The Company believes the mechanism of action of bempikibart has the potential to be active in other Th2 and Th1 driven diseases, including asthma, COPD, ulcerative colitis (UC), rheumatoid arthritis (RA), celiac disease, multiple sclerosis (MS) and others. "These impressive biomarker data represent a meaningful advancement in the clinical understanding of how inhibition of IL-7Rα can be leveraged to treat autoimmune and inflammatory diseases," said Shelia Violette , Ph.D., Co-Founder and Chief Scientific Officer of Q32 Bio. "Based upon its observed mechanism of action, bempikibart continues to show strong potential as an IL-7Rα inhibitor to treat AA and other diseases." The Company has published an updated investor presentation with additional details regarding the bempikibart update for review by interested parties. The updated presentation can be found on the company website at www.Q32Bio.com under Investors & Media. About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases being evaluated in a Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, being evaluated in a Phase 2 program, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. For more information, visit www.Q32Bio.com . Availability of Other Information About Q32 Bio Investors and others should note that we communicate with our investors and the public using our company website www.Q32Bio.com , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, our beliefs, observations, expectations and assumptions regarding the topline data from the SIGNAL-AA Phase 2a and the safety, tolerability, clinical activity including biomarker data, potential efficacy and potential benefits of bempikibart; plans and expectations for Part B of the SIGNAL-AA Phase 2a clinical trial are forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support our current beliefs and expectations for bempikibart, future clinical studies, including the Part B of the SIGNAL-AA Phase 2a clinical trial, may not be completed in a timely manner or at all, might be more costly than expected or might not yield anticipated results, the Company may need additional funding to complete its clinical studies, which may not be available on favorable terms or at all, and such other risks and uncertainties identified in the Company's periodic, current and other filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and any subsequent filings with the Commission, which are available at the SEC's website at www.sec.gov . Any such risks and uncertainties could materially and adversely affect the Company's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on the Company's stock price. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Contacts: Investors: Brendan Burns Media: Sarah Sutton Argot Partners 212.600.1902 Q32Bio@argotpartners.com View original content to download multimedia: https://www.prnewswire.com/news-releases/q32-bio-provides-bempikibart-program-update-including-next-steps-for-advancing-alopecia-areata-development-program-302328042.html SOURCE Q32 BioSocial Media Dad Predicts Major Shifts in Digital Landscape for 2025, Parents Need to Buckle Up
- Previous: is jilibet legit
- Next: jilibet 004 login philippines
